Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients.
Non-Small-Cell Lung Carcinoma
About this trial
This is an interventional treatment trial for Non-Small-Cell Lung Carcinoma focused on measuring Non-small cell lung carcinoma, radiotherapy, mean lung dose
Eligibility Criteria
Inclusion Criteria: Histologically proven non-small cell lung cancer UICC stage I-III WHO performance status 0-2 Less than 10 % weight loss the last 6 months In case of previous chemotherapy, radiotherapy can start after a minimum of 21 days after the last chemotherapy course Reasonable lung function: FEV1 ³ 60 % of the predicted value No recent ( < 3 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction) No active peptic oesophagitis Life expectancy more than 6 months Measurable cancer Willing and able to comply with the study prescriptions 18 years or older Not pregnant and willing to take adequate contraceptive measures during the study Have given written informed consent before patient registration No previous radiotherapy to the chest Exclusion Criteria: Not non-small cell histology, e.g. mesothelioma, lymphoma Mixed pathology, e.g. non-small cell plus small cell cancer Malignant pleural or pericardial effusion Concurrent chemotherapy with radiation History of prior chest radiotherapy Recent ( < 3 months) myocardial infarction Uncontrolled infectious disease Distant metastases (stage IV) Patients with active peptic oesophagitis in the last year. Less than 18 years old Pregnant or not willing to take adequate contraceptive measures during the study
Sites / Locations
- Maastircht Radiation Oncology